Triangle8/12-Day Production of Car-T Cells (NCT04186520)
8/12-Day Production of Car-T Cells trial for Non Hodgkin Lymphoma (NHL) (NCT04186520). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
When B-cell lymphoma comes back after CAR T therapy, one common reason is that the cancer drops the target, CD19, from its surface.
The idea: aim at two targets at once, and build the cells faster, in the hospital that treats the patient.
At the Medical College of Wisconsin, a patient's T cells receive a receptor that recognizes both CD19 and CD20. They are grown on site in eight to twelve days, not shipped away for weeks, with interleukin-7 and -15 to keep younger, longer-lasting cells.
In seventeen patients with relapsed mantle cell lymphoma, every one responded, and eighty-eight percent completely.
Nirav Shah leads the trial in Milwaukee, now extending to other lymphomas, CLL, and lymphoma in the brain. Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.